TL;DR
Anthropic has opened a physical wet lab in the San Francisco Bay Area, pairing Claude AI with robotic systems to run real biology experiments, targeting diseases pharma ignores and aiming to compress scientific timelines by "an order of magnitude."
What happened
- Anthropic confirmed a physical wet lab in the San Francisco Bay Area, with head of life sciences Eric Kauderer-Abrams stating experiments are already underway.
- The lab pairs Claude AI with robotic automation (liquid handlers, robotic arms, plate readers) so AI agents can coordinate multi-step experiments with limited human intervention.
- In August, Anthropic released the Model Hardware Standard, a common interface letting Claude communicate with lab instruments; a Genentech demo showed Claude coordinating a full protein assay and adjusting parameters in real time.
- Anthropic acquired Coefficient Bio (reported at roughly $400 million in stock) and added Novartis CEO Vas Narasimhan to its board, signaling serious institutional commitment.
- Life sciences is now among Anthropic's largest investment areas by headcount and resources, per Kauderer-Abrams.
Why it matters
- The wet lab moves Anthropic from AI-as-advisor to AI-as-laboratory-operator, a qualitative shift where Claude directs physical experiments rather than just summarizing papers or suggesting protocols.
- The stated goal is an "autonomous discovery engine": scientists set the biological objective, AI handles routine physical execution, analysis, and iteration, potentially compressing research cycles dramatically.
- Anthropic is explicitly targeting rare and "undruggable" diseases that large pharma skips for financial reasons, including complex bispecific and trispecific antibodies, carving a lane that avoids direct competition with customers like Genentech, Bristol Myers Squibb, and Novo Nordisk.
- CEO Dario Amodei's personal motivation (his father died shortly before a cure for his disease emerged) adds urgency and signals this is a long-term strategic priority, not a marketing exercise.
- The move benchmarks directly against Isomorphic Labs (Alphabet's drug-discovery arm), which has spent years trying to reach the clinic and only recently pushed that milestone to end of 2026.
What to watch next
- Whether Anthropic discloses specific disease programs or preclinical results, which would signal the lab is producing real science rather than capability demonstrations.
- Adoption of the Model Hardware Standard by third-party biotech and pharma labs: broad uptake would make Claude the default AI layer for automated biology, locking in a platform advantage.
- Any move toward clinical trials or a drug-development spinout, which Anthropic has explicitly ruled out for now but which would be the logical next step if preclinical work succeeds.
Originally published on Present of AI, a daily source-linked AI news timeline. Read the full timeline or browse the open dataset.